Zymeworks (ZYME)
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms in...
- Open
- 26.610
- High
- 26.785
- Low
- 25.810
- Prev. Close
- 26.850
- Volume
- 552.16K
- Turnover
- 14.39M
- Avg Price
- 26.052
- Bid/Ask Ratio
- --
- Amplitude
- 3.63%
- 52wk High
- 31.340
- Volume Ratio
- 1.44
- Turnover Ratio
- 0.84%
Zymeworks Analyst Rating
View moreForecast & Rating
Sep 9, 2026Price forecast
$41.7560.27%
Forecast & RatingStrong buy
12analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- businessinsider · Sep 10 at 03:15 PM
Theravance facing several lawsuits seeking to block Zymeworks acquisition
- PUBT · Sep 10 at 01:11 PM
Theravance Biopharma announces shareholder meeting on merger deal
- Market Beat · Sep 3 at 09:24 PM
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00
- Market Beat · Aug 27 at 10:12 AM
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings
